New York City, NY – According to filings with the U.S. Securities and Exchange Commission, Cambrian BioPharma is raising $4,750,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, James Peyer played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cambrian BioPharma

Cambrian Biopharma is a private, clinical-stage biopharmaceutical company focused on developing therapies to prevent and cure age-related diseases. Cambrian is based in New York City with operations across the US and Europe. Cambrian is focused on the basic biology of aging, a field known as ‘geroscience.’ The company has a network of collaborations with leading aging-focused academic labs, partnering early to spin out newcos and progress assets into the clinic.

To learn more about Cambrian BioPharma, visit http://www.cambrianbio.com/

Contact:
James Peyer, Chief Executive Officer
516-962-3186
https://www.linkedin.com/in/jamespeyer/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved